AR033659A1 - El compuesto 2-(3,5-bis -trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida), su uso, un procedimiento para prepararlo y un medicamento que lo contiene - Google Patents
El compuesto 2-(3,5-bis -trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida), su uso, un procedimiento para prepararlo y un medicamento que lo contieneInfo
- Publication number
- AR033659A1 AR033659A1 ARP000106217A ARP000106217A AR033659A1 AR 033659 A1 AR033659 A1 AR 033659A1 AR P000106217 A ARP000106217 A AR P000106217A AR P000106217 A ARP000106217 A AR P000106217A AR 033659 A1 AR033659 A1 AR 033659A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- bis
- phenyl
- prepare
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- -1 3,5-BIS -TRIFLUORMETHYL-PHENYL Chemical class 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- ZGNPLCMMVKCTHM-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-morpholin-4-ylpyridin-3-yl]propanamide Chemical compound C=1N=C(N2CCOCC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZGNPLCMMVKCTHM-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 abstract 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99123685 | 1999-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033659A1 true AR033659A1 (es) | 2004-01-07 |
Family
ID=8239481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000106217A AR033659A1 (es) | 1999-11-29 | 2000-11-27 | El compuesto 2-(3,5-bis -trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida), su uso, un procedimiento para prepararlo y un medicamento que lo contiene |
Country Status (49)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144717A0 (en) | 1999-02-24 | 2002-06-30 | Hoffmann La Roche | Phenyl-and pyridinyl derivatives |
| EP1035115B1 (en) * | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| PT1303490E (pt) * | 2000-07-14 | 2008-09-04 | Hoffmann La Roche | Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina |
| TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
| KR20040077910A (ko) * | 2002-01-31 | 2004-09-07 | 에프. 호프만-라 로슈 아게 | 프리프로타키키닌 유전자의 유전자 다형성 |
| ES2291891T3 (es) | 2003-07-03 | 2008-03-01 | F. Hoffmann-La Roche Ag | Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia. |
| US7288658B2 (en) | 2003-07-15 | 2007-10-30 | Hoffmann-La Roche Inc. | Process for preparation of pyridine derivatives |
| CN1984891B (zh) | 2004-07-06 | 2012-08-08 | 弗·哈夫曼-拉罗切有限公司 | 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法 |
| CA2598762A1 (en) | 2005-02-25 | 2006-08-31 | F. Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
| CA2602445C (en) | 2005-03-23 | 2013-08-20 | F.Hoffmann-La Roche Ag | Metabolites for nk-i antagonists for emesis |
| ATE453384T1 (de) | 2005-09-23 | 2010-01-15 | Hoffmann La Roche | Neue dosierformulierung |
| US8093268B2 (en) | 2007-01-24 | 2012-01-10 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| BR112015021982B1 (pt) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| CA2930008A1 (en) | 2013-11-08 | 2015-05-14 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
| AP2016009261A0 (en) | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| KR101948238B1 (ko) | 2016-08-19 | 2019-02-14 | (주)케어젠 | 미녹시딜과 펩타이드의 결합체 |
| KR102328682B1 (ko) | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2149767T5 (es) * | 1991-09-20 | 2005-06-16 | Glaxo Group Limited | Nuevo uso medico para antagonistas de taquiquininas. |
| CA2099233A1 (en) * | 1992-06-29 | 1993-12-30 | Conrad P. Dorn | Morpholine and thiomorpholine tachykinin receptor antagonists |
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| IL112134A (en) * | 1993-12-29 | 1999-12-22 | Merck Sharp & Dohme | Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them |
| IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| EP0733632B1 (en) * | 1995-03-24 | 2003-06-04 | Takeda Chemical Industries, Ltd. | Cyclic compounds, their production and use as tachykinin receptor antagonists |
| US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| EP1035115B1 (en) * | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
| PT1303490E (pt) * | 2000-07-14 | 2008-09-04 | Hoffmann La Roche | Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina |
| TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
-
2000
- 2000-11-21 DE DE60006340T patent/DE60006340T2/de not_active Expired - Lifetime
- 2000-11-21 SI SI200030246T patent/SI1103545T1/xx unknown
- 2000-11-21 TR TR2003/02077T patent/TR200302077T4/xx unknown
- 2000-11-21 PT PT00125450T patent/PT1103545E/pt unknown
- 2000-11-21 ES ES00125450T patent/ES2208205T3/es not_active Expired - Lifetime
- 2000-11-21 EP EP00125450A patent/EP1103545B1/en not_active Expired - Lifetime
- 2000-11-21 AT AT00125450T patent/ATE253561T1/de active
- 2000-11-21 DK DK00125450T patent/DK1103545T3/da active
- 2000-11-23 GB GB0028566A patent/GB2356863A/en not_active Withdrawn
- 2000-11-23 AU AU71787/00A patent/AU775292B2/en not_active Expired
- 2000-11-23 CA CA002326529A patent/CA2326529C/en not_active Expired - Lifetime
- 2000-11-23 NZ NZ508386A patent/NZ508386A/xx unknown
- 2000-11-23 JO JO2000187A patent/JO2298B1/en active
- 2000-11-23 IL IL139868A patent/IL139868A/en active IP Right Grant
- 2000-11-23 YU YU73400A patent/YU73400A/sh unknown
- 2000-11-23 PE PE2000001254A patent/PE20010901A1/es not_active Application Discontinuation
- 2000-11-24 CZ CZ20004399A patent/CZ299286B6/cs not_active IP Right Cessation
- 2000-11-24 JP JP2000356833A patent/JP3480835B2/ja not_active Expired - Lifetime
- 2000-11-24 IS IS5725A patent/IS2212B/is unknown
- 2000-11-24 FR FR0015193A patent/FR2801590A1/fr not_active Withdrawn
- 2000-11-24 HR HR20000809A patent/HRP20000809A2/hr not_active Application Discontinuation
- 2000-11-24 SG SG200006945A patent/SG97171A1/en unknown
- 2000-11-24 DE DE10058310A patent/DE10058310A1/de not_active Withdrawn
- 2000-11-24 PA PA20008507201A patent/PA8507201A1/es unknown
- 2000-11-26 GC GCP20001052 patent/GC0000151A/xx active
- 2000-11-27 MX MXPA00011672A patent/MXPA00011672A/es active IP Right Grant
- 2000-11-27 CO CO00090625A patent/CO5251405A1/es active IP Right Grant
- 2000-11-27 MY MYPI20005527A patent/MY127426A/en unknown
- 2000-11-27 GE GEAP20005644A patent/GEP20022763B/en unknown
- 2000-11-27 SK SK1793-2000A patent/SK285373B6/sk unknown
- 2000-11-27 HU HU0004725A patent/HU224703B1/hu active IP Right Grant
- 2000-11-27 AR ARP000106217A patent/AR033659A1/es unknown
- 2000-11-27 ZA ZA200006964A patent/ZA200006964B/xx unknown
- 2000-11-28 GT GT200000197A patent/GT200000197A/es unknown
- 2000-11-28 SV SV2000000227A patent/SV2002000227A/es unknown
- 2000-11-28 MA MA26111A patent/MA26754A1/fr unknown
- 2000-11-28 UY UY26458A patent/UY26458A1/es not_active Application Discontinuation
- 2000-11-28 BR BRPI0005616A patent/BRPI0005616B8/pt not_active IP Right Cessation
- 2000-11-28 ES ES200002839A patent/ES2171134A1/es not_active Withdrawn
- 2000-11-28 UA UA2000116781A patent/UA70326C2/uk unknown
- 2000-11-28 NO NO20006012A patent/NO317264B1/no not_active IP Right Cessation
- 2000-11-28 DO DO2000000106A patent/DOP2000000106A/es unknown
- 2000-11-28 EA EA200001114A patent/EA004404B1/ru not_active IP Right Cessation
- 2000-11-28 BG BG104992A patent/BG64622B1/bg unknown
- 2000-11-28 KR KR10-2000-0071141A patent/KR100390117B1/ko not_active Expired - Lifetime
- 2000-11-28 PL PL344147A patent/PL195957B1/pl unknown
- 2000-11-29 IT IT2000MI002575A patent/IT1320120B1/it active
- 2000-11-29 OA OA1200000324A patent/OA11513A/fr unknown
- 2000-11-29 CN CNB001342606A patent/CN1152016C/zh not_active Expired - Lifetime
- 2000-11-29 TN TNTNSN00226A patent/TNSN00226A1/fr unknown
- 2000-11-29 ID IDP20001029D patent/ID28483A/id unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2171134A1 (es) | Procedimiento para la preparacion del pompuesto 2-(3,5-bis-trifluorometil-fenil)-n-,etil-n-(6-morfolin-4-il-o-tolil-priridin-3-il)-isobutiramida. el producto per se, y su uso para la preparacion de medicamentos. | |
| AR009052A1 (es) | Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas | |
| BR0314393A (pt) | Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia | |
| ES2134859T3 (es) | Derivados de 4-carboxoamido-piperidina, productos intermedios y uso como antagonistas de neurokinina. | |
| AR036208A1 (es) | Compuesto polimorfo estable de flibanserina, procedimiento industrial para su preparacion, y uso del mismo para preparar medicamentos | |
| BR0112756A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto | |
| ECSP055747A (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos | |
| ES2163071T3 (es) | Sulfonamidas y su utilizacion. | |
| BR9910583A (pt) | Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios | |
| CO4810373A1 (es) | Compuestos azapoliciclicos condensados con arilo | |
| ECSP055746A (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos | |
| AR028988A1 (es) | Derivados amida, proceso para su preparacion, composicion farmaceutica que los comprende, y su uso en la fabricacion de un medicamento util en el tratamiento de enfermedades o afecciones clinicas mediadas por citoquinas | |
| GT199800046A (es) | Compuestos de pirazina. | |
| PT1263730E (pt) | Derivados amina para o tratamento de apoptose | |
| UY27592A1 (es) | Nuevo uso | |
| AR006360A1 (es) | Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion. | |
| BRPI0415769A (pt) | alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as | |
| AR028475A1 (es) | Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion. | |
| AR029461A1 (es) | Derivados de 4-fenil-1-piperazinilo, - piperidinilo y -tetrahidropiridilo , composiciones farmaceuticas que los comprenden y el uso de los mismos para la fabricacion de un medicamento | |
| AR005102A1 (es) | Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento. | |
| AR027578A1 (es) | Derivados de indano | |
| UY29823A1 (es) | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones | |
| BRPI0413101A (pt) | compostos de sulfonamida derivado de benzoxazinona, sua preparação e uso como medicamentos | |
| UY26079A1 (es) | Nuevos derivados de morfolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR035915A1 (es) | Compuesto de {(2r)-2-[4-(4-{2-[(-metilsulfonil) amino]-etil} fenil) fenil) propil} [(metiletil) sulfonil) amina y sales farmaceuticamente aceptables del mismo; composiciones farmaceuticas que comprenden dicho compuesto; metodo para potenciar la funcion glutamato; para tratar estados depresivos; y ar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |